MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice - 17/01/16

Doi : 10.1016/j.tube.2015.10.010

Nacho Aguilo ^a,^b,^{^{1
These authors share senior authorship.}}, Santiago Uranga ^a,^b, Dessislava Marinova ^a,^b, Marta Monzon ^c, Juan Badiola ^c, Carlos Martin ^a,^b,^d,^⁎,^{^{1
These authors share senior authorship.}}
^a Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain
^b CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
^c Research Centre for Encephalopathies and Transmissible Emerging Diseases, Universidad de Zaragoza, 50013 Zaragoza, Spain
^d Servicio de Microbiología, Hospital Universitario Miguel Servet, ISS Aragón, 50009 Zaragoza, Spain

^∗Corresponding author. Dpto. Microbiología, Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Zaragoza, C/ Domingo Miral s/n, 50009 Zaragoza, Spain. Tel.: +34 976 76 17 59; fax: +34 976 76 16 64.

Summary

Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.

Le texte complet de cet article est disponible en PDF.

Keywords : MTBVAC, Newborn mice, Tuberculosis vaccine, Neonates

Plan

Results and discussion

Safety evaluation

Immunogenicity evaluation

Protective efficacy evaluation

Conclusions

Export

Vol 96

P. 71-74 - janvier 2016 Retour au numéro

Article précédent

Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques
Sally Sharpe, Andrew White, Fergus Gleeson, Anthony McIntyre, Donna Smyth, Simon Clark, Charlotte Sarfas, Dominick Laddy, Emma Rayner, Graham Hall, Ann Williams, Mike Dennis

| Article suivant

Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of Mycobacterium tuberculosis infection in rhesus macaques
Laura Sibley, Mike Dennis, Charlotte Sarfas, Andrew White, Simon Clark, Fergus Gleeson, Anthony McIntyre, Emma Rayner, Geoffrey Pearson, Ann Williams, Philip Marsh, Sally Sharpe

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice - 17/01/16

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL